How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial

CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by concomitant drugs, which can lead to a clinical phenotype that is different from the genotype‐based phenotype, a process referred to as phenoconversion. Phenoconversion is highly prevalent but not widely integrated into practice because of either limited experience on how to integrate or lack of knowledge that it has occurred. We built a calculator tool to help clinicians integrate a standardized method of assessing CYP2D6 phenoconversion into practice. During tool‐building, we identified several clinical factors that need to be considered when implementing CYP2D6 phenoconversion into clinical practice. This tutorial shares the steps that the University of Florida Health Precision Medicine Program took to build the calculator tool and identified clinical factors to consider when implementing CYP2D6 phenoconversion in clinical practice.

[1]  J. T. Deen,et al.  A Hybrid Implementation-Effectiveness Randomized Trial of CYP2D6 Guided Post-operative Pain Management , 2021, Genetics in Medicine.

[2]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy , 2021, Clinical pharmacology and therapeutics.

[3]  M. Pirmohamed,et al.  A Review of the Important Role of CYP2D6 in Pharmacogenomics , 2020, Genes.

[4]  H. Guchelaar,et al.  Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review , 2020, Journal of clinical medicine.

[5]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing , 2020, Clinical pharmacology and therapeutics.

[6]  I. Zineh,et al.  Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug‐Drug Interaction Risks , 2020, Clinical pharmacology and therapeutics.

[7]  S. J. Sklar,et al.  Interpretation of Cytochrome P‐450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation , 2020, Clinical pharmacology and therapeutics.

[8]  S. Bielinski,et al.  Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics , 2020, Pharmacogenomics and personalized medicine.

[9]  R. Vossen,et al.  A unifying model to predict variable drug response for personalised medicine , 2020, bioRxiv.

[10]  Julie A. Johnson,et al.  A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications , 2020, Clinical pharmacology and therapeutics.

[11]  E. Pearson,et al.  Drug–drug–gene interactions and adverse drug reactions , 2019, The Pharmacogenomics Journal.

[12]  Maitreya J. Dunham,et al.  Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity , 2019, Clinical and translational science.

[13]  M. Relling,et al.  Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group , 2019, Clinical and translational science.

[14]  Julie A. Johnson,et al.  Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings , 2019, Genetics in Medicine.

[15]  R. Shelton,et al.  Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing , 2019, Genetics in Medicine.

[16]  R. Fillingim,et al.  CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial , 2019, Genetics in Medicine.

[17]  I. Bitter,et al.  Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure , 2019, European Archives of Psychiatry and Clinical Neuroscience.

[18]  K. Byron,et al.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes , 2018, Journal of Neural Transmission.

[19]  Y. Daali,et al.  Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions , 2018, Clinical pharmacology and therapeutics.

[20]  C. Draucker,et al.  CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. , 2017, Applied nursing research : ANR.

[21]  Michelle Whirl-Carrillo,et al.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.

[22]  Carolyn R Rohrer Vitek,et al.  Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. , 2016, Mayo Clinic proceedings.

[23]  H. Williams,et al.  What is a pragmatic clinical trial? , 2015, The Journal of investigative dermatology.

[24]  R. Shah,et al.  Addressing phenoconversion: the Achilles' heel of personalized medicine , 2015, British journal of clinical pharmacology.

[25]  T. Mamiya,et al.  How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. , 2014, Pharmacogenomics.

[26]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.

[27]  A. Gaedigk.  Complexities of CYP2D6 gene analysis and interpretation , 2013, International review of psychiatry.

[28]  S. Preskorn,et al.  Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. , 2013, The Journal of clinical psychiatry.

[29]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[30]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[31]  Isabelle Ragueneau-Majlessi,et al.  A useful tool for drug interaction evaluation: The University of Washington Metabolism and Transport Drug Interaction Database , 2010, Human Genomics.

[32]  Zeruesenay Desta,et al.  Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients , 2010, Journal of clinical pharmacology.

[33]  R. Altman,et al.  Cytochrome P450 2D6. , 2009, Pharmacogenetics and genomics.

[34]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[35]  E. Begg,et al.  Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice , 2006, Pharmacological Reviews.

[36]  Sung-joon Min,et al.  Posthospital medication discrepancies: prevalence and contributing factors. , 2005, Archives of internal medicine.

[37]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[38]  L. Ereshefsky,et al.  CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady‐State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6 , 2002, Pharmacotherapy.

[39]  L. Bertilsson,et al.  Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test , 2001, Clinical pharmacology and therapeutics.

[40]  R. Goldberg,et al.  Discrepancies in the use of medications: their extent and predictors in an outpatient practice. , 2000, Archives of internal medicine.

[41]  L. Bertilsson,et al.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. , 2000, British journal of clinical pharmacology.